SIGLEC9 and cervical carcinoma: The study indicates that MUC1, secreted by cervical cancer cells, interacts with SIGLEC9 on macrophages and T-cells, promoting TAMs differentiation and inhibiting T-cell function, ultimately contributing to immune evasion in cervical cancer.